evipedia.ai
← Back

Lactobacillus sakei to Treat Sinusitis

Evidence Review created on 09/25/2026 using AI4L / Opus 5.5

Also known as: Latilactobacillus sakei, L. sakei, Lactobacillus sake, Lactobacillus sakei subsp. sakei, proBio65, Lanto Sinus

Motivation

Lactobacillus sakei (also written Latilactobacillus sakei) is a bacterium found in fermented foods such as kimchi, sake starter and cured sausage, and in small numbers in the healthy human nose. Interest in it as a sinus treatment grew from one observation: the bacterium, though never abundant, is more common in healthy sinuses than in chronically inflamed ones, which raised the question of whether putting it back could calm long-running sinus disease.

Long-lasting sinus inflammation is common, difficult to treat, and often returns after repeated antibiotic courses or surgery. Over the past decade, attention has shifted from eliminating single disease-causing bacteria toward the whole microbial community of the nose and sinuses, and several helpful bacteria — this one among them — have been proposed as ways to rebuild that community rather than deplete it further.

This review examines what is known about Lactobacillus sakei applied to sinus disease: where the idea came from, what laboratory, animal and human studies show, what is known about its safety, how it is now being tested, and where the evidence stops, so that the idea can be weighed against what has actually been shown in people.

Benefits - Risks - Protocol - Conclusion

High-level overviews of Lactobacillus sakei and of bacterial approaches to sinus disease, from expert commentary and primary research.

Note on the priority-expert search: web and on-site searches found no relevant content from Peter Attia, Andrew Huberman, Life Extension Magazine or Lifespan.io on Lactobacillus sakei or nasal bacterial therapy. Rhonda Patrick’s FoundMyFitness carries only a news story on a kimchi-derived L. sakei strain binding nanoplastics in the gut; it does not address sinus disease, so it is not listed.

Grokipedia

  • Latilactobacillus sakei

    Covers taxonomy, the 1934 sake-starter isolation, bacteriocin (small antibacterial protein) production and food use, and includes a short section on nasal application for chronic sinus disease and the ongoing trial.

Examine

No dedicated Examine article exists for Lactobacillus sakei. A direct site search returns only pages for other species, a genus glossary entry, and one members-only research-feed summary of an L. sakei OK67 body-fat trial, which does not address sinus disease.

ConsumerLab

No ConsumerLab article exists for Lactobacillus sakei. A site search for “sakei” returns no results at all, and the broader search returns only the general probiotic review and unrelated warning letters.

Systematic Reviews

Systematic reviews and meta-analyses covering bacterial therapy for sinus disease and the safety of these organisms; none is specific to Lactobacillus sakei.

Both the claimed benefit and the principal risk are represented above, but only at class and genus level; none addresses Lactobacillus sakei itself.

Mechanism of Action

Four mechanisms are proposed, none yet confirmed in human sinuses.

First, competitive exclusion: Lactobacillus sakei occupies adhesion sites and consumes nutrients that sinus pathogens need. In the mouse work that launched the field (Abreu et al., 2012), applying it together with Corynebacterium tuberculostearicum reduced that pathogen’s numbers while leaving L. sakei counts intact.

Second, direct antibacterial output. The species secretes sakacins (class II bacteriocins: small antibacterial proteins) plus lactic acid and hydrogen peroxide, which lower local pH and inhibit Staphylococcus aureus and Listeria, organisms it competes with in fermented meat.

Third, epithelial barrier support. Lactic acid bacteria reorganise tight junction proteins (the seals between surface cells) through TLR2–TLR6 signalling (a pattern-recognition pathway of the innate immune system); barrier leakiness is a feature of chronic sinus disease.

Fourth, immune modulation: in a mouse allergic airway model run by the strain’s developer, HEM Pharma, intranasal L. sakei lowered type 2 inflammation (the allergy-associated arm of the immune response) and allergy antibody levels (Kim et al., 2023).

Competing explanations exist. One view holds that lactobacilli must colonise the nose to work — the species carries catalase genes and other adaptations suggesting genuine residence there. The opposing view is that transient passage suffices, benefit coming from secreted products rather than persistence, which would make repeated dosing necessary. A third position questions the premise: depleted lactobacilli may be a consequence of inflammation and antibiotic exposure rather than its cause, in which case replacing them would not reverse disease.

Historical Context & Evolution

The species was first isolated in 1934 from moto, the starter mash for Japanese sake, and for six decades was studied as a food organism: a cold-tolerant, salt-tolerant fermenter used to ripen sausage, kimchi and fermented fish and, through its sakacins, to suppress Listeria in cured meat. Its health applications began in Korea, where a kimchi-derived strain (proBio65) was deposited in 2004 and patented for inhibition of Staphylococcus aureus growth and for anti-allergic effects.

The sinus connection dates to 2012. A University of California, San Francisco group compared sinus brushings from patients undergoing surgery with those of healthy controls, and found not a single culprit pathogen but a collapse of bacterial diversity: over 1,400 bacterial types were depleted, with lactic acid bacteria — L. sakei prominent among them — most reduced, while one species, Corynebacterium tuberculostearicum, expanded (Abreu et al., 2012). In mice, that species produced goblet cell (mucus-producing cell) overgrowth and mucus hypersecretion when the resident community was first stripped by antibiotics, and L. sakei prevented that damage.

Two paths followed. Commercially, refrigerated single-strain L. sakei powders appeared, driven largely by online self-experimentation. Scientifically, progress was slow: the 2020 European sinus guideline (Fokkens et al., 2020) advised against probiotics; its authors, mostly ear, nose and throat surgeons, earn practice revenue from the surgery and prescription treatments it endorses, not from probiotics. That position rests on absent trials of this species, not failed ones — the first randomised L. sakei sinus trial began enrolling only in 2025.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: each benefit rests on a single randomised trial showing a between-group improvement over placebo on a validated clinical scale, and the second eczema trial reports within-group changes only.

Medium 🟩 🟩

Reduced Atopic Dermatitis Severity ⭕️ Not Central to Treat Sinusitis

Oral Lactobacillus sakei reduced eczema severity, measured with SCORAD (a validated eczema scoring scale), in one randomised placebo-controlled trial in children; a second trial in children and adolescents reported within-group improvement only. The proposed mechanism is suppression of Staphylococcus aureus on skin plus lowered chemokines that recruit inflammatory cells into skin. This bears on allergic skin disease, not on sinus symptoms. Both trials were in Korean paediatric populations; no adult replication exists.

Magnitude: Mean SCORAD improved 31% (13.1 points) with L. sakei versus 13% (5.2 points) with placebo over 12 weeks in 88 children (Woo et al., 2010); a second 90-participant trial, run by the strain’s manufacturer Probionic, found significant within-group reductions for live and heat-killed cells but not placebo (Rather et al., 2021).

Reduced Knee Osteoarthritis Pain and Stiffness ⭕️ Not Central to Treat Sinusitis

A single exploratory randomised placebo-controlled trial in adults with knee osteoarthritis (joint degeneration) found better pain, stiffness and physical function scores on WOMAC (a validated osteoarthritis index) after 12 weeks of an oral strain, alongside a fall in interleukin-1β (a pro-inflammatory messenger). This bears on joint symptoms rather than sinus disease, but is the strongest current evidence that oral dosing of this species can shift a systemic inflammatory signal in humans. The trial was run with the strain’s developer, LISCure Biosciences, and was explicitly exploratory.

Magnitude: Total WOMAC fell 4.07 points versus a 2.15-point rise on placebo (between-group p = 0.009; p values below 0.05 mark results unlikely to be due to chance) and pain on a 100 mm visual analogue scale fell 16.5 versus 8.8 mm in 92 analysed participants (Shine et al., 2025).

Improved Dry Eye Signs with Topical Lysate ⭕️ Not Central to Treat Sinusitis

In a factorial randomised placebo-controlled trial (one testing drops and capsules separately and together), eye drops containing a Lactobacillus sakei lysate (bacterial fragments, no live organism) improved dry eye symptoms and tear film measures and lowered tear interleukin-6, tumour necrosis factor alpha and interferon gamma (inflammatory messengers). Oral capsules of the live organism produced no effect in the same trial. This bears on ocular surface inflammation, and is notable because it separates a local non-living preparation from systemic live dosing.

Magnitude: All three endpoints — the Ocular Surface Disease Index (a symptom questionnaire), tear break-up time (how long the tear film stays intact) and the Schirmer I test (a tear-volume strip test) — improved with active drops versus placebo over 4 weeks in 40 patients (all p < 0.0001), with no benefit from oral capsules; the accessible report gives significance levels but no effect-size figure (Heydari et al., 2024).

Low 🟩

Reduced Body Fat and Visceral Fat ⚠️ Conflicted ⭕️ Not Central to Treat Sinusitis

Two 12-week placebo-controlled trials of oral kimchi-derived strains, sponsored by their makers (CJ CheilJedang; Dongwha Pharm), disagree: one lowered total body fat, the other only visceral fat. This bears on body composition, not sinus disease. Strain differences plausibly explain this. Net reading: a small fat effect is possible but inconsistent.

Magnitude: Body fat mass differed by 0.8 kg versus placebo and waist circumference by 0.8 cm in 114 adults (Lim et al., 2020); visceral fat area fell significantly (p = 0.035) with no body fat difference in 100 adults (Oh et al., 2023).

Improved Skin Elasticity ⭕️ Not Central to Treat Sinusitis

One 8-week placebo-controlled trial of heat-treated oral cells in 60 healthy women, run by the strain’s maker Kaneka, improved skin elasticity but not skin moisture or water loss. This bears on skin ageing, not sinus disease. The elasticity gain was significant at 5 weeks only, and the cells were non-living.

Magnitude: Skin recovery rate (a suction-device elasticity measure) rose 5.9 percentage points versus 2.8 with placebo at 5 weeks (between-group p = 0.022), narrowing to a non-significant 6.6 versus 3.4 at 8 weeks, in 50 analysed women (Sawashita et al., 2025).

Speculative 🟨

Protection of Sinus Mucosa Against Pathogen-Driven Inflammation

The central claim. In antibiotic-depleted mice, L. sakei prevented the mucus overproduction caused by Corynebacterium tuberculostearicum. Basis is animal data only; no human outcome exists (Abreu et al., 2012).

Damping of Allergic Airway Inflammation

Intranasal dosing of developer HEM Pharma’s kimchi-derived strain reduced type 2 inflammation and strengthened epithelial barrier in mouse lungs; nasal and sinus tissue were not examined. Basis is animal work only (Kim et al., 2023).

Direct Inhibition of Sinus Pathogens

Strains of this species secrete sakacins and acidify their surroundings, inhibiting Staphylococcus aureus and other organisms in culture. Basis is in-vitro inhibition assays; such assays have repeatedly failed to predict clinical sinus benefit (Cervin, 2018).

Benefit-Modifying Factors

  • Sinus endotype (the biological subtype driving disease): Chronic sinus disease splits into bacterial subgroups, each dominated by a different pathogen family and each driving a distinct immune response (Cope et al., 2017); which subgroup, if any, responds to this species is untested.

  • Genetic variation: No polymorphism is known to modify response to this species. Variants in sinonasal innate immunity, notably the bitter taste receptor gene TAS2R38, alter antibacterial defence and could plausibly shift who benefits, but this is untested.

  • Baseline biomarkers: Low sinus bacterial diversity and low resident lactobacilli define the deficit the intervention targets; high blood eosinophil (allergy-linked white blood cell) counts and high total IgE (immunoglobulin E, the antibody class behind allergic responses) mark the subtype less likely to respond.

  • Sex differences: No sex-based difference in response has been reported for this species. Chronic sinus disease is somewhat more often diagnosed in women, but no trial of L. sakei has been large enough to detect a sex difference.

  • Pre-existing conditions and age: Prior sinus surgery leaves sinuses wide open, which is why the registered trial requires it — access determines exposure. Ageing reduces upper-airway microbial diversity and slows the mucus flow that clears the sinuses, plausibly lowering retention in older adults.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no Lactobacillus sakei trial has documented any adverse event more often than placebo, and the bloodstream-infection evidence comes from genus-level case series.

Medium 🟥 🟥

No risk reaches Medium: the bloodstream-infection evidence consists of uncontrolled, genus-level case series and a class-level umbrella review, not a trial or consistent observational data on this species.

Low 🟥

Invasive Infection in Immunocompromised or Critically Ill Users

Lactobacilli can enter the bloodstream in people with severe illness, central venous catheters or immunosuppression. An umbrella review flagged sepsis in vulnerable populations. Evidence is uncontrolled, mostly genus- or class-level; one septic arthritis (joint infection) case was attributed to L. sakei (Cabrera Romero et al., 2025), none to nasal application.

Magnitude: In a series of 89 patients with Lactobacillus bacteraemia (bacteria in the bloodstream), 82% had severe or fatal coexisting illnesses, mortality was 26% at one month and 48% at one year, and severe underlying disease was the strongest predictor of death (Salminen et al., 2004); the umbrella review located its sepsis signal in vulnerable paediatric populations (Hoang & Kim, 2026).

Mild Gastrointestinal and Tolerability Complaints with Oral Use

Transient bloating, flatulence and loose stools are the usual complaints with oral lactic acid bacteria. Randomised trials of oral L. sakei found adverse events mild and no more frequent than placebo, so this risk is extrapolated from the class. All trials lasted 12 weeks or less.

Magnitude: In 114 adults, adverse events were mild and did not differ between groups (Lim et al., 2020); in 100 adults, no adverse events or serious adverse events were reported over 12 weeks (Shine et al., 2025).

Amoebic Brain Infection from Contaminated Irrigation Water

Tap water used for nasal irrigation can carry Naegleria fowleri, an amoeba that travels from the nose to the brain and causes an almost uniformly fatal infection. The hazard lies in the irrigation water, not the bacterium, but applies to every rinse-based protocol. Evidence is case investigations only.

Magnitude: Two fatal cases in Louisiana in 2011 were traced to tap-water sinus irrigation with neti pots, with the amoeba found in both households’ water (Yoder et al., 2012).

Local Nasal Irritation and Nosebleed with Intranasal Use

A systematic review of probiotic trials in chronic sinus disease reports nosebleed (Fong et al., 2023), and a pilot trial of another bacterium delivered into the nose found no new sinus infections (Endam et al., 2020). Evidence for L. sakei by this route in humans does not yet exist.

Magnitude: Direction is toward mild, self-limiting local effects, holding where sinuses are surgically opened and irrigation is short-term; the literature reports no incidence figure for this species by this route.

Speculative 🟨

Transfer of Antibiotic Resistance Genes

Lactic acid bacteria can in principle carry transferable resistance genes; characterised probiotic strains of this species test negative, but unscreened food isolates may not. Basis is genomic screening only.

Delay of Effective Treatment for Bacterial Sinusitis

Substituting an unproven product for care in acute bacterial sinusitis could postpone effective treatment, with spread beyond the sinuses the feared consequence. Basis is reasoning only; no case series exist.

Risk-Modifying Factors

  • Immune status: Neutropenia (too few infection-fighting white cells, below 500/µL) or a CD4 count under 200 cells/µL (few immune T-cells) raises invasive-infection risk from any live organism — the dominant modifier.

  • Genetic variation: No polymorphism is known to alter risk from this species. Primary immunodeficiencies affecting neutrophil or antibody function are the relevant inherited modifier, acting through the same route as acquired immunosuppression.

  • Baseline biomarkers: Neutrophil count, CD4 count and markers of active systemic infection (elevated C-reactive protein, a general inflammation marker) identify the state in which live bacteria are least appropriate.

  • Pre-existing conditions: Prosthetic or damaged heart valves, central venous catheters, short bowel syndrome (loss of most small intestine) and cerebrospinal fluid leak (brain fluid draining through a skull-base opening into the nose) turn a benign exposure into a seeding route.

  • Sex and age differences: No sex-based difference in adverse effects has been reported for this species. Advanced age matters indirectly, through the coexisting illness and immunosenescence (age-related immune decline) that underlie almost all reported lactobacilli bloodstream infections.

Key Interactions & Contraindications

  • Oral and topical antibiotics (amoxicillin-clavulanate, doxycycline, mupirocin, topical tobramycin irrigations): Caution. They kill the organism, nullifying the intervention. Mitigation: oral dosing separated by 2–3 hours; no concurrent antibacterial nasal preparation.

  • Antiseptic and antibacterial nasal products (povidone-iodine rinses, baby shampoo irrigations, colloidal silver, xylitol at antibacterial concentrations): Caution. They inactivate live bacteria on contact. Mitigation: no combination in the same irrigation, which the commercial product’s labelling also states.

  • Manuka honey and other antibacterial irrigation additives: Caution. Their antibacterial action extends to lactobacilli, plausibly cancelling the intended effect. Mitigation: alternation rather than combination; no interaction study exists.

  • Immunosuppressants (prednisone, tacrolimus) and biologics (engineered antibody drugs: rituximab, dupilumab): Caution, with the first three raising invasive-infection risk from any live organism. Mitigation: clinician oversight, and avoidance during active immunosuppression.

  • Intranasal corticosteroids (anti-inflammatory steroid nasal sprays: mometasone, fluticasone) and saline irrigation: No interaction known; saline is the comparator in the registered trial. Monitor only. Saline irrigation itself alters upper-airway microbial diversity, a confounder rather than a hazard.

  • Other probiotics and prebiotics (multi-strain oral products; inulin and fructo-oligosaccharides, fibres that feed gut bacteria): Additive rather than harmful; they increase total live organism load. Monitor in immunocompromised users, where cumulative exposure is the relevant quantity.

Populations who should avoid Lactobacillus sakei:

  • Neutropenia (absolute neutrophil count <500/µL) or CD4 count <200 cells/µL
  • Solid organ or haematopoietic stem cell (bone marrow) transplant recipients on active immunosuppression
  • Indwelling central venous catheters, prosthetic heart valves, or prior infective endocarditis (heart valve infection)
  • Critical illness requiring intensive care, or active systemic infection
  • Cerebrospinal fluid leak, skull-base defect, or sinus surgery within the preceding 12 months
  • Short bowel syndrome or other severe intestinal barrier failure
  • Pregnancy and breastfeeding, where nasal use is untested

Risk Mitigation Strategies

  • Immune-status screening before use: A complete blood count with differential establishes that neutrophils are adequate, addressing the invasive-infection risk that accounts for essentially all reported lactobacilli bloodstream events.

  • Conventional assessment of acute infection first: Fever, one-sided facial pain, pus-like discharge beyond ten days or worsening after improvement are the features warranting medical assessment, which prevents delayed treatment of a bacterial infection.

  • Short, symptom-triggered courses: Product labelling and the registered trial both use roughly 14 days rather than indefinite dosing, limiting cumulative exposure and the dryness and irritation reported with over-frequent nasal application.

  • Sterile, distilled or boiled-and-cooled water for irrigation: Tap water in nasal irrigation carries a documented risk of amoeba infection entirely separate from the probiotic; this precaution eliminates it.

  • Separation from antibacterial products: Spacing oral doses 2–3 hours from antibiotics, and no antiseptic nasal preparation alongside, prevents the interaction that silently makes the intervention inert.

  • Discontinuation at any new or worsening local symptom: Nosebleed, persistent irritation or increasing pain are the local adverse effects seen with nasal bacterial preparations, and are reversible on discontinuation.

Therapeutic Protocol

  • Registered trial regimen (topical): The only controlled protocol: a commercial L. sakei proBio65 powder packet dissolved in 240 mL of distilled or boiled water, irrigated twice daily for 14 days, in adults with sinuses previously opened surgically (NCT05427695).

  • Oral regimens from published trials: Trials in other conditions used roughly 1 × 10¹⁰ colony-forming units (a count of live bacteria) daily for 12 weeks; no oral regimen has been tested for sinus outcomes.

  • Competing approach — topical versus oral: Topical delivery targets the diseased surface; oral delivery relies on immune signalling from the gut. Neither is established as superior, and the dry eye trial found benefit only locally (Heydari et al., 2024).

  • Competing approach — conventional care: Saline irrigation, intranasal corticosteroids, culture-directed antibiotics and, for polyp disease, type 2 biologics have the larger trial record; bacterial therapy has been tested with and without them, and no trial compares the two directly.

  • Who popularised each approach: Cervin argued for topical sinus probiotics (Cervin, 2018); Desrosiers’ Montreal group tested Lactococcus lactis by sinus irrigation (Endam et al., 2020); Victoria Lee (University of Illinois at Chicago) leads the L. sakei trial (NCT05427695).

  • Self-applied practitioner approach: Mara Silgailis’s blog Lacto Bacto popularised placing small amounts of kimchi juice directly into the nostrils, an approach publicised by Chris Kresser; it has never been tested for safety or efficacy.

  • Time of day: No time-of-day effect has been studied. Practitioner accounts favour application when the nose is clearest — typically after the morning saline rinse and again in the evening.

  • Persistence rather than half-life: This organism has no pharmacological half-life. Related nasal lactobacilli are cleared within days of a single application, which is the rationale for twice-daily rather than weekly dosing.

  • Split versus single dosing: Topical protocols split into two daily applications on the assumption of rapid clearance; oral trials used single or twice-daily dosing with no head-to-head comparison.

  • Genetic polymorphisms and dose: No pharmacogenetic variant is known to influence dose choice, since the intervention is not metabolised by host enzymes. Variation in innate mucosal defence genes remains a theoretical, untested modifier.

  • Sex-based differences: No sex-specific dosing difference has been reported or tested; trials in eczema, obesity and osteoarthritis used identical regimens for both sexes.

  • Age considerations: Trials span children through adults to age 75. Older adults have slower mucociliary clearance (the mucus-sweeping action of the airway lining), which may prolong local contact but has never been dose-adjusted for.

  • Baseline biomarkers and response: Pre-treatment sinus culture and microbial profiling define the deficit being targeted; the registered trial tracks the amount of bacteria and which types are present as its secondary endpoint.

  • Pre-existing conditions and response: Unoperated, obstructed sinuses limit access of any irrigation to the target; the registered trial excluded cystic fibrosis, autoimmune sinonasal disease and immunocompromise as predisposing to infectious complications.

Discontinuation & Cycling

  • Short-term rather than lifelong: Both the registered trial and product labelling frame use as a defined 14-day course rather than indefinite supplementation, with reassessment afterwards rather than automatic continuation.

  • No withdrawal effects: No withdrawal syndrome has been described for any lactic acid bacterium. Stopping simply removes the exposure; the organism is cleared from mucosal surfaces within days.

  • Tapering not applicable: No tapering protocol exists or is proposed; trials stopped dosing abruptly at the end of the treatment period, with no rebound worsening reported.

  • Symptom-triggered rather than continuous cycling: Practitioner and product guidance favours re-treating only when symptoms return, explicitly discouraging routine maintenance doses — an approach untested in any trial.

  • Return of symptoms after stopping: Benefits of another nasal bacterium persisted two weeks after treatment (Endam et al., 2020); a systematic review found lower relapse risk 8 months later (Fong et al., 2023). Recurrence after L. sakei is unstudied.

Sourcing and Quality

  • Live count and refrigeration: Viable counts decline with warmth and time. Products that state colony-forming units at manufacture and ship refrigerated are the only ones where the labelled dose is meaningful at the point of use.

  • Strain identity on the label: A bare species name is insufficient; effects in this genus are strain-specific. The only strain used in a registered sinus trial is proBio65, deposited in the Korean Collection for Type Cultures as KCTC 10755BP.

  • Third-party testing: Independent verification of identity, live count and absence of contaminants matters more here than for most supplements, because the product is applied to a mucosal surface rather than taken orally.

  • Manufacturing standards: Production under Good Manufacturing Practice, with lot-level testing, is the practical floor. ConsumerLab has not tested any single-strain L. sakei product, so no independent comparison exists.

  • Fermented foods as a source: Kimchi and some sauerkraut contain the species transiently, but strain identity, live count and presence vary by brand and fermentation stage, making food an uncontrolled and unverifiable source.

  • Products and suppliers: Lanto Sinus is the single-strain refrigerated powder used in the registered trial; sausage starter cultures containing this species are sold for food use and are neither formulated nor tested for human mucosal application.

Practical Considerations

  • Time to effect: The registered trial measures symptoms at two and six weeks. Practitioner and user accounts describe changes within days, but no controlled human data on onset exist for sinus outcomes.

  • Common pitfall — combining with antibacterials: Using the product alongside antiseptic rinses, antibiotic irrigations or manuka honey silently inactivates it, producing an apparent failure that reflects the combination rather than the organism.

  • Common pitfall — improvised preparations: Self-devised nasal preparations from food or food-industry cultures have no safety, sterility or dose data behind them, and are not what any trial tested.

  • Common pitfall — indefinite use: Continuous application beyond a short course is associated in user reports with nasal and throat dryness, and has never been studied.

  • Regulatory status: In the United States these are dietary supplements, not approved drugs; no product is approved for treating sinus disease. The trial version is regulated as an investigational drug.

  • Cost and accessibility: Roughly $50 for a 15 g refrigerated jar, shipped with a cold pack — expensive relative to saline but not prohibitive. Availability is limited to a small number of direct suppliers.

  • Payer incentives: Supplements are not reimbursed, whereas surgery and type 2 biologics costing thousands per year are; no payer or manufacturer stands to recoup large trials of an unpatentable organism, a structural bias in research funding and guideline formation.

Interaction with Foundational Habits

  • Sleep: Indirect and bidirectional. Nasal obstruction from sinus disease fragments sleep and drives mouth breathing; any measure that improves nasal airflow plausibly improves sleep quality. No direct effect of this organism on sleep architecture has been studied, and the reverse direction — poor sleep impairing mucosal immunity — is the better-established link.

  • Nutrition: Direct and supportive. Fermented vegetables supply this species and related lactic acid bacteria, and fermentable fibre supports the broader microbial community; alcohol and high-sugar intake are associated with worse sinus symptoms. Antibacterial dietary additions such as high-dose garlic extract or manuka honey may work against a live preparation.

  • Exercise: Largely independent, with one practical point: aerobic exercise briefly opens the nasal passages by narrowing blood vessels in the nasal lining, and chlorinated pool water irritates sinus mucosa. No blunting or potentiation of this intervention by training has been described, and no timing relative to dosing is established.

  • Stress management: Indirect. Chronic stress raises cortisol, which suppresses mucosal antibody secretion and is associated with more frequent upper-respiratory infection — the setting in which sinus disease relapses. No study has measured whether this organism alters cortisol or the stress response in humans.

Monitoring Protocol & Defining Success

Baseline assessment establishes both the target and the safety floor before any live organism is applied. That means a symptom score and an endoscopic examination to document disease activity, an endoscopically guided sinus culture to identify what is actually colonising the sinuses, and a complete blood count with differential to confirm immune competence — the single measurement that governs whether live bacteria are appropriate at all. Inflammatory and allergy markers separate the bacterial-colonisation pattern from the eosinophilic pattern that responds to other treatments.

Ongoing monitoring follows the registered trial’s cadence: symptom score at baseline, at the end of a two-week course, and again at six weeks, with endoscopy and repeat culture at the six-week point. Where treatment is repeated over time, an annual review of symptom burden, antibiotic courses required and any new immune-compromising condition is the practical interval.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
SNOT-22 score <20; a fall of ≥9 points defines meaningful change Primary measure of sinus symptom burden SNOT-22 = Sino-Nasal Outcome Test, a 22-item validated symptom questionnaire; self-completed, best done at the same time of day
Lund-Kennedy endoscopic score 0–2 (scale 0–20, lower is better) Objective mucosal appearance: polyps, swelling, discharge, crusting Requires nasal endoscopy by a clinician; pair with the symptom score, which it often does not track closely
Endoscopically guided sinus culture No dominant pathogen; mixed resident, harmless bacteria Identifies whether Staphylococcus aureus or Corynebacterium dominance is present — the pattern this intervention targets Swabs of the nostril opening are not equivalent; conventional culture under-reports the community that bacterial gene sequencing (16S rRNA, a gene used to identify bacteria) reveals
Absolute neutrophil count 1,800–7,000/µL Safety gate: identifies the neutropenia that underlies invasive infection risk from live organisms Part of a complete blood count with differential; conventional labs flag only values below 1,500/µL
Blood eosinophil count <200 cells/µL Separates type 2 (eosinophilic, polyp-associated) disease, which responds to other treatments Conventional reference range extends to 500 cells/µL; values above 300 predict polyp recurrence
Serum total IgE <100 IU/mL Marks the allergic endotype less likely to respond to bacterial competition IgE = immunoglobulin E, the antibody class driving allergic responses; no fasting required
High-sensitivity C-reactive protein <1.0 mg/L General systemic inflammation; rules out active infection before live-organism use Conventional cut-off is 3.0 mg/L; invalid within two weeks of any acute illness
25-hydroxyvitamin D 40–60 ng/mL Low status is associated with worse sinus disease and impaired mucosal defence Conventional sufficiency starts at 30 ng/mL; draw any time of day, but keep supplementation stable for 8 weeks beforehand

Qualitative markers to track alongside the laboratory values:

  • Nasal airflow and the ability to breathe through both nostrils overnight
  • Sense of smell, the symptom patients most often rank as most disabling
  • Facial pressure and headache frequency
  • Post-nasal discharge, its colour and volume
  • Number of antibiotic courses and days of missed work per year
  • Sleep quality and daytime energy, both of which track sinus symptom burden

Emerging Research

  • First randomised trial of this species in sinus disease: NCT05427695, a phase 2 (mid-stage efficacy testing) double-blind trial at the University of Illinois at Chicago, randomises 60 adults with previously operated sinuses to L. sakei proBio65 or saline irrigation twice daily for 14 days, with SNOT-22 at six weeks as the primary endpoint.

  • Completed trial of a different nasal organism: NCT04048174 applied Lactococcus lactis W136 by irrigation in 24 patients with treatment-refractory sinus disease, finding it safe and associated with symptom, endoscopic and microbiome changes (Endam et al., 2020).

  • Mechanistic follow-up that could strengthen the case: Gene-activity profiling of the sinus lining after that treatment showed shifts in epithelial regeneration and non-type 2 immune pathways, giving a testable mechanism rather than a symptom score alone (Al-Romaih et al., 2023).

  • Nasal delivery of adapted lactobacilli: NCT03587545 was registered to test whether upper-airway-adapted Lactobacillus strains survive after nasal spray application in a planned 120 participants (current status unknown), following work showing these organisms genuinely colonise the nose (De Boeck et al., 2020).

  • Findings that could weaken the case: A sham-controlled crossover trial (each patient received the bacterial spray and a dummy spray in turn) of a nasal lactic acid bacterial mixture in sinus disease changed neither symptoms, nor flora, nor inflammatory markers — the clearest demonstration that in-vitro pathogen inhibition need not translate (Mårtensson et al., 2017).

  • Oral dosing already shown to fail: A randomised trial of oral Lactobacillus rhamnosus found no sinus quality-of-life benefit over placebo, arguing that the delivery route, not merely the strain, is what needs to be right (Mukerji et al., 2009).

  • Open question on microbiome shift versus symptom relief: Nasal rinsing with other probiotic species reduced several inflammation-associated bacterial genera without demonstrated symptom benefit, raising the possibility that microbiome correction and symptom relief are separable outcomes (Brożek-Mądry et al., 2025).

Conclusion

Lactobacillus sakei is a food-fermenting bacterium that lives in small numbers in healthy noses and is scarce in chronically inflamed ones. That contrast, plus a mouse study in which it shielded sinus lining from a pathogen’s damage, is the whole foundation of its use for sinus disease — a well-argued idea with no human result behind it yet.

What the human record does show is different: taken orally, this bacterium eased eczema in children and joint pain in adults, with less consistent effects on body fat and skin elasticity, while eye drops made from its fragments helped dry eyes. None of that concerns the sinuses, and the one trial comparing oral with local use found benefit only locally.

Safety looks favourable but is incompletely mapped. Short oral courses have been well tolerated, with side effects no more common than with placebo. The serious concern — bacteria entering the bloodstream — comes from the wider family and has occurred almost only in people who were already severely ill or immune-suppressed; nothing is known about nasal application of this organism in people.

The evidence base is thin: several oral trials were funded by the strain makers, and much rests on one research group’s animal work. The European guideline advising against such products was written largely by surgeons, whose income comes from other treatments. The first controlled trial in sinus disease is now under way; until it reports, the case rests on plausibility rather than results in people.

Top - Benefits - Risks - Protocol